To Identify if a COPD Self-management App Can Safety and Appropriately Identify When Patients Are Not on the Best Medication Plan for Their COPD Symptoms and Support Their COPD Management. (mySmartCOPD)
To Explore the Safety and Clinical Efficacy of a Treatment Realignment Algorithm Using Data From a Digital Self-management Application for Patients With COPD
Although COPD cannot be cured, managing COPD can help reduce symptoms control, slows progression of the disease, and may improve the quality of life. Management of COPD becomes less effective when healthcare professionals fail to prescribe appropriate inhaled therapies, due to poor adherence to evidence-based guidelines and underdiagnosis, or when patients fail to adhere to prescribed treatment regimens.
my mhealth has developed an app called myCOPD to allow patients to record their COPD symptoms and medications, which in term supports them with their COPD. This app is now used by COPD patients across the UK, via a prescription from their healthcare professionals. my mHealth has now developed a research app MMH-LAB1 which, in the intervention arm, includes an algorithm to assist patients with understanding their level of symptom burden according to the severity of their daily symptoms and exacerbation risk. The algorithm then analyses current patient prescribed inhaled medication against those recommended by the GOLD 2023 report and informs the patient via the MMH-LAB1 app as to whether their medication needs to be changed by their healthcare provider. This trial will explore whether the introduction of the algorithm within the MMH-LAB1 app can be used as a safe, effective and acceptable tool to assist patients to achieve optimal guideline based inhaled therapy and therefore provide greater symptom control and lowered exacerbation risk for COPD patients.
Participants will be randomised to the MMH-LAB1 app - control arm (MMH-LAB_Control_1 where participants just record COPD symptoms and medications), or to the MMH_LAB1 app - intervention arm (MMH-LAB1_Test_1 where participants record their COPD symptoms and medication plus receiving information from the algorithm, as to whether their medications are in guidance or not, and if not, be notified to visit their healthcare professional.
調査の概要
状態
状態
条件
条件
介入・治療
介入・治療
詳細な説明
This study is an open-label randomised control trial with inbuilt pilot phase and qualitative sub-study:
Phase 1 (pilot - 50 participants): Interim futility analysis on adherence to intervention advice Phase 2 (efficacy - 746 participants (including pilot phase participants): Safety acceptability and efficacy of intervention. This includes the qualitative sub study 15-20 participants (from the 746 Phase 2 participants).
Qualitative Sub-study: Acceptability of the intervention (15-20 intervention participants)
This trial will explore whether the introduction of the treatment realignment algorithm can be used as a safe, effective and acceptable tool to assist patients to achieve optimal, guideline based inhaled therapy and therefore provide greater symptom control and lowered exacerbation risk for COPD patients. To assess effect of the intervention on patients' symptom control, including exacerbation frequency and patient wellness scores.
Main objectives
- To understand the intervention pathway in the pilot phase and to identify additional patient support mechanisms for the efficacy phase in order to maximise healthcare equality
- To assess the levels of app usage and engagement
- To assess patients' experience of using the intervention
Study Design:
Open-Label Randomised Control Trial with inbuilt pilot phase Qualitative Sub study:
Phase 1 (Pilot): Interim futility analysis on adherence to intervention advice Phase 2 (Efficacy): Safety, acceptability and efficacy of intervention Qualitative Sub-study: Acceptability of the intervention.
The research question is to explore the safety and efficacy of the treatment re-alignment algorithm as part of a digital self-management application (app) in patients with COPD.
研究の種類
研究の種類
入学 (推定)
入学
段階
段階
- フェーズ 1
連絡先と場所
研究連絡先
研究連絡先
- 名前:Trial Manager
- 電話番号:+44 23 8059 6920
- メール:mysmartcopd@soton.ac.uk
研究場所
-
-
England
-
Southampton、England、イギリス、SO16 6YD
- 募集
- University Hospital Southampton
-
コンタクト:
- Tom Wilkinson, MA Cantab MBBS PhD FRCP FERS
- 電話番号:02381 205341
- メール:T.Wilkinson@soton.ac.uk
-
-
参加基準
適格基準
適格基準
就学可能な年齢
- 大人
- 高齢者
健康ボランティアの受け入れ
説明
Inclusion Criteria:
- Adult patients over 18 years of age and able to give informed consent
- A clinical diagnosis of COPD (all patients registered on the app have a confirmed diagnosis of COPD confirmed by their clinician before being prescribed the app).
- A registered and activated user of the myCOPD app
- One or more CAT questionnaire completed on the myCOPD app in the last 12 months
- One or more exacerbation form completed on the myCOPD app in the last 12 months CTU/FORM/5321 - CIP template for Clinical Investigations of Medical Devices, Version 1 14-DEC-2023 mySmartCOPD Clinical Investigation Plan v1 25-FEB-2025 Page 25 of 53
- One or more COPD medication diary completed on the myCOPD app in the last 12 months
Classified appropriately into 3 groups:
(A) Few symptoms (CAT <10, 0 or 1 moderate exacerbations) (B) Many symptoms (CAT ≥10, ≥0 or 1 moderate exacerbations) (C)Exacerbators (≥2 moderate or ≥1 severe exacerbation independent of CAT)
Exclusion Criteria:
- Cannot read or write in English as required to understand the trial materials and provide the trial data.
- Has not opted in to the research agreement via MyCOPD
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:支持療法
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
アーム数
武器と介入
参加者グループ / アーム参加者グループ / アーム |
介入・治療介入・治療 |
|---|---|
|
プラセボコンパレーター:MMH-LAB1 Control This arm is based on the original COPD app the participants already use
Participants for this study are already users of a COPD self management app.
This arm is a replica of this app, with additional questionnaires built in
|
This app is based on a COPD self management app, which they are already using and includes an algorithm which will notify participants if there is a discrepancy between the symptoms they report onto the app and their medication regime, and informs them to approach their healthcare provider for a medication review
|
|
実験的:MMH-LAB1 Test This arm is based on the original COPD app the participants use plus an algorithm
Participants for this study are already users of a COPD self management app.
This arm is a replica of this app, with additional questionnaires built in plus an algorithm which identifies, based on the symptoms and medication reported onto the app by the participant, whether they are on the correct medication or not.
If not, the app will generate a notification and inform the participant that they need to approach their healthcare provider and inform them of this and that they need a medication review.
|
This app is based on a COPD self management app, which they are already using and includes an algorithm which will notify participants if there is a discrepancy between the symptoms they report onto the app and their medication regime, and informs them to approach their healthcare provider for a medication review
|
この研究は何を測定していますか?
主要な結果の測定
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
To determine the safety, acceptability and efficacy of a digital treatment guidance algorithm for inhaled treatment in patients with COPD. The intention is to measure the impact of the algorithm in prompting patients to achieve optimal management, and t
時間枠:6 months
|
Proportion (measured in %) of participants receiving guideline adherent treatment at Baseline and trial completion (Month 6).
Range 0%-100%.
|
6 months
|
二次結果の測定
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
To assess effect of intervention on exacerbation frequency and patient wellness scores
時間枠:6 months
|
• Change in COPD Assessment Test (CAT) score between Baseline and trial completion (Month 6) CAT test results 0 minimal symptom impact - Best and 40 maximum symptom impact All will be described in terms of:
|
6 months
|
|
To assess effect of the intervention on patients' adherence to guideline mandated treatment
時間枠:6 months
|
- Rate of indication of algorithm to change treatment (0 times to 150 times) • Rate if change in response to treatment change indication (0 times to 150 times) All measured via frequency and percentage and description of change. The combination of measurements will be reported as descriptive stats |
6 months
|
|
To understand the utility of the intervention pathway in the pilot phase and to identify additional patient support mechanisms for the efficacy phase in order to maximise healthcare equality
時間枠:6 months
|
- % Patients receiving guideline adherent treatment at Baseline and trial completion (Month 6). 100% good. 0 % bad. Above described qualitatively and in terms of % and frequency |
6 months
|
|
To assess the levels of app algorithm usage and engagement
時間枠:6 months
|
-Frequency of app engagement
Measured by frequency (numbers of participant who completed everything) % (0% of expected use bad and 100% of expected use good). This will be reported as descriptive stats. |
6 months
|
|
To understand patients' experience of using the intervention
時間枠:3-6 months - interviews. 6 months - feedback questionnaire
|
This section relates to the qualitative sub-study and will look at the following: - Patient experience and patient and patient advocate feedback on experience of using app • Patient satisfaction Rating using the Patient Using feedback questionnaire at month 6 and qualitative interviews as part of the sub -study
This will be reported in a separate analysis document using qualitative research analysis and reporting techniques and norms |
3-6 months - interviews. 6 months - feedback questionnaire
|
|
To assess the safety of the algorithm
時間枠:6 months
|
• Rate of algorithm inappropriately firing notifications This is data collected via MMHLAB apps and qualitatively via patient advocate.
|
6 months
|
|
To assess the change in frequency of exacerbations
時間枠:6 months
|
Frequency of exacerbation between Baseline and trial completion (Month 6) • Frequency and percentages (for number of exacerbations) Frequency will be measured from 0-150 with 0 being optimal.
This will be reported as descriptive stats.
|
6 months
|
|
To assess the change in Quality of Life between baseline and 6 months
時間枠:6 months
|
Change in Quality of Life.
Ratings measured using EQ-5D questionnaire between Baseline and trial completion (Month 6).
All will be described in terms of: • Mean and SD • Median and range.
Score 11111 will be classed as full health and 55555 will be classed worst health.
This will be reported as descriptive stats
|
6 months
|
協力者と研究者
研究記録日
主要日程の研究
研究開始 (実際)
研究開始
一次修了 (推定)
一次修了
研究の完了 (推定)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (実際)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
キーワード
その他の研究ID番号
その他の研究ID番号
- 355764
- AI_Award02200 (その他の助成金/資金番号:UK - National Institute for Health and Care Research)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。